PAION AG is a publicly listed specialty pharmaceutical company headquartered in Aachen (Germany) with further sites in Cambridge (United Kingdom) and New Jersey (USA). PAION's lead substance, remimazolam, is an intravenous ultra-short-acting benzodiazepine sedative/anesthetic currently in Phase III clinical development for procedural sedation. Remimazolam is designed to complement and improve currently available treatment options for patients requiring sedation and anesthesia. PAION is focusing its clinical development activities on remimazolam according to PAION's vision to become an acknowledged “PAIONeer” in sedation and anesthesia.
What does PAIONeering mean to us? PAIONeering means engineering the medical future, forging new paths and setting benchmarks. We have short lines of communication that make it easy to take decisions and respond quickly. A true PAIONeer is not a lone warrior, but rather a committed team player who knows that the only way to achieve our ambitious goals is to do it together. We expect flexibility and a hands-on working style from our employees. There is no room for coveting status at PAION - our work is about responsibility, achievement and room for growth.
Market capitalization (21-Sep-2017)
Closing share price (21-Sep-2017)